The biotech’s pipeline features bispecifics against a range of targets, including one candidate that hits PD-L1 and TGFβ and ...

Arcus Biosciences unveiled data from a terminated late-stage study of its TIGIT and PD-1 drug combo that it says supports its ...

Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...

The finance round was led by OrbiMed and comes almost exactly two years after Mereo decided to pull a US IPO, blaming challenging market conditions. In the phase 1b combination study, a total of ...

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Among its late-stage pipelines, we assign a very low probability of 10% to its phase 3 project on Ociperlimab, an anti-TIGIT antibody, after Roche failed its TIGIT pivotal trial in July 2024. Hence, ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Additional sub-studies would permit the evaluation of COM701 as a backbone treatment in combination with agents like ...

Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Read More on ITOS: ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

This study is a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, versus ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...